BMJ Open Diabetes Research & Care最新文献

Introduction: Emerging adults with chronic conditions, such as type 1 diabetes (T1D), face vulnerability during transition to adulthood and transfer to adult care. Facilitating transition preparation, disease-related knowledge acquisition, self-management, and follow-up has proved to improve transition readiness and experiences. Few studies exist on conditions related to emerging adults' transition and transfer, and how these associate with other relevant variables. The purpose of this study was to describe experiences of emerging adults with T1D regarding transitional care before transfer, and to explore potential correlates of these experiences.

Research design and methods: A cross-sectional study including 162 emerging adults with T1D was performed at eight Swedish adult diabetes clinics. The primary outcome was transition and transfer experiences measured by TEXP-Q (Transitional care EXPeriences Questionnaire)-a novel PREM (patient-reported experience measure). Correlations between TEXP-Q and sex, glycated hemoglobin, time to follow-up, empowerment, the healthcare climate in adult care, and diabetes self-efficacy were investigated.

Results: The mean average score of TEXP-Q (range 1-5) was 3.6±0.7 for the total scale, and for subscales: Healthcare-provider communication 4.5±0.7, autonomy and participation 3.5±0.9, and transition and transfer preparation 3.0±1.1. Sex proved to be significant only for transition and transfer preparation (p=0.004), demonstrating better perceived preparation among men compared with women. Positive experiences from transition and transfer were associated with higher level of empowerment (rho 0.34, p<0.001), diabetes self-efficacy (rho 0.32, p<0.001) and satisfaction with the healthcare climate in adult care (rho 0.36, p<0.001).

Conclusion: In this study we used a novel measure, TEXP-Q, to explore experiences of transitional care preparation among emerging adults with T1D. While most participants reported high satisfaction with the healthcare-provider communication, fewer reported feeling sufficiently prepared for the transition and transfer processes. The potential correlates investigated could not with conviction be regarded as important for the transition and transfer experiences. Using TEXP-Q in clinical practice may provide vital information when evaluating existing healthcare practices for emerging adults with T1D, and when planning for improvement of care offered to emerging adults in preparation for transition and transfer.

Introduction: Limited research has focused on the prospective influence of insulin resistance (IR) on new-onset chronic kidney disease (CKD) in healthy screening populations. Therefore, we aimed to investigate how IR, assessed via the estimated glucose disposal rate (eGDR), and metabolism-related comorbidities influence new-onset CKD.

Research design and methods: This two-stage retrospective cohort study (cross-sectional and longitudinal analyses) used data from health check-up participants at the Chinese People's Liberation Army General Hospital (2009-2021). The cross-sectional analysis included 83 346 participants with or without CKD; the longitudinal analyses included 13 738 participants without prior CKD who visited the hospital at least two times. The cross-sectional phase of this study analyzed the relationship between IR and CKD; the longitudinal phase analyzed the relationship between IR and new-onset CKD. The mediating role of metabolism-related comorbidities was also explored.

Results: In the cross-sectional analysis, 6.77% (n=5643) of patients had prior CKD. The eGDR was significantly higher in the non-CKD group than in the CKD group (9.16±2.11 vs 7.19±2.32, p<0.001). Higher eGDR was associated with lower CKD prevalence (OR: 0.91, 95% CI: 0.89 to 0.93, P for trend<0.001). In the cohort analysis, the average time to trigger endpoint events was 2.95±2.02 years, with 403 (2.93%) new-onset CKD cases reported. A linear correlation was observed between eGDR and new-onset CKD (p<0.001), with higher eGDR linked to reduced CKD risk (HR: 0.88, 95% CI: 0.82 to 0.96, P for trend=0.002). Mediation analysis revealed significant indirect effects of diabetes mellitus (17.1%), systolic blood pressure (22.0%), glycated hemoglobin (11.1%), and brachial-ankle pulse wave velocity (9.7%) (all p<0.05).

Conclusions: IR is independently linked to new-onset CKD, with blood glucose, blood pressure, and arterial stiffness mediating this relationship. These findings underscore the importance of managing IR and metabolic comorbidities to prevent CKD onset in at-risk populations.

Introduction: Social determinants of health (SDoH) are key risk factors impacting diabetes outcomes. The American Diabetes Association has identified five principal SDoH categories influencing diabetes outcomes: socioeconomic status, neighborhood and physical environment, food environment, healthcare, and social context. Currently, no concise and valid instruments exist to measure the burden of SDoH factors for individuals with diabetes. To fill this gap, we developed the Diabetes Index for Social Determinants of Health (DISDOH).

Research design and methods: Participants with type 1 and type 2 diabetes were recruited from the regional Health Extension for Diabetes (HED) programme and a national crowdsourcing platform. Item development through a diabetes expert stakeholder group yielded a pool of 16 items, which were further refined through piloting with individuals living with diabetes. Principal component analysis was conducted with a sample of 440 HED participants, identifying a 5-factor solution. Confirmatory factor analysis supported this 5-factor solution using 215 individuals with type 1 and type 2 diabetes. Reliability and validity of DISDOH were also assessed.

Results: The five DISDOH domains demonstrated acceptable internal consistency estimates: Domain 1, socioeconomic status (a=0.660); Domain 2, neighborhood and physical environment (a=0.812); Domain 3, food environment (a=0.801); Domain 4, health context (a=0.812); and Domain 5, social context (a=0.708). DISDOH showed strong convergent validity with related SDoH measures, and divergent validity was supported by weak or non-significant correlations with distinct constructs.

Conclusions: DISDOH is the first validated, diabetes-specific SDoH assessment designed for brief, practical use in clinical and community settings. Unlike existing instruments, which are often lengthy and not tailored to diabetes management, DISDOH offers a concise yet comprehensive approach to identifying social risk factors that impact diabetes self-care and outcomes.

Introduction: No direct comparisons have evaluated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) versus metformin as first-line antidiabetic therapy for preventing dementia in patients with type 2 diabetes mellitus (T2DM). This study aimed to assess the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk.

Research design and methods: This retrospective cohort study used data from a global health research network between 2004 and 2024. Patients with T2DM initiating GLP-1 RAs or metformin as first-line monotherapy were included. Propensity score matching was employed to balance baseline characteristics. Dementia incidence was analyzed using Cox proportional hazards models, with sensitivity analyses to confirm robustness.

Results: Among 87,229 matched patients per cohort, GLP-1 RA use was associated with a significantly lower risk of overall dementia (adjusted HR (AHR) 0.90; 95% CI 0.85 to 0.95), Alzheimer's disease (AD) (AHR 0.88; 95% CI 0.83 to 0.94), and non-vascular dementias (non-VaDs) (AHR 0.75; 95% CI 0.70 to 0.81) compared with metformin. No significant difference was observed for VaD. Subgroup analyses showed consistent benefit across age and sex, with the strongest effect among older adults and females.

Conclusions: GLP-1 RAs were more effective than metformin in reducing the risk of dementia-especially AD and non-vascular types-highlighting their potential as a preferred first-line treatment in T2DM. Further randomized trials are warranted to validate these findings.

Introduction: Lower extremity arterial disease (LEAD) represents a significant atherosclerotic complication in patients with type 2 diabetes (T2D). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and metformin are commonly prescribed glucose-lowering agents that have demonstrated potential benefits in attenuating atherosclerosis progression. This study examined the impact of SGLT2is and metformin on the risk of developing severe LEAD in elderly patients with T2D.

Research design and methods: This retrospective cohort study analyzed insurance data for individuals aged 65 years and older with advanced-age health insurance coverage, using health insurance claims and self-reported health check-up data. The observation start date was the initial prescription date of SGLT2is or metformin. Severe LEAD was defined as cases requiring revascularization after a LEAD diagnosis. We conducted a 3-year analysis using propensity score matching to compare the distinct effects of each drug on LEAD risk using a claims database.

Results: The final population comprised 31,732 new SGLT2i and metformin users, divided into two groups (n=15,866 patients each). LEAD incidence rates were 2.10 and 2.69 per 1,000 person-years for metformin and SGLT2is, respectively. Compared with metformin, SGLT2is showed a higher HR for severe LEAD, especially in patients with a diastolic blood pressure (dBP) below 80 mm Hg (HR: 2.11; 95% CI: 1.01 to 2.30) and an estimated glomerular filtration rate between 30 and 60 mL/min/1.73 m² (HR: 2.32; 95% CI: 1.09 to 2.94).

Conclusion: The endothelial benefits of metformin, achieved without affecting hemodynamics, may be particularly effective in elderly patients with T2D and low dBP or impaired renal function. However, the presence of cardiovascular disease may often lead to the selection of SGLT2is. Nevertheless, prioritizing the use of metformin may be prudent when considering LEAD status.

Introduction: Family history (FmH) of young-onset type 2 diabetes (YOD) and 1-hour plasma glucose (PG) during the 75-g oral glucose tolerance test predicts incident diabetes, although their interactions remain unknown.

Research design and methods: In a workforce cohort established in 1998-2003, we ascertained their glycemic status in 2012-2014. We examined the interaction between FmH-YOD and 1-hour PG in predicting diabetes and used receiver operating characteristics (ROC) analysis to compare the performance of 1-hour PG in participants with or without FmH-YOD.

Results: Among 583 participants (median age (IQR)=41 (36-47) years, 43.7% men, body mass index=23.3 (21.2-26) kg/m², 40.3% (n=235) had FmH-YOD, 1-hour PG=8.1 (6.4-10.1) mmol/L), 99 (17%) had developed diabetes at a follow-up of 12.1 (11.3-13.1) years. In the FmH-YOD group, 45% in the high 1-hour PG group and 17% in the normal 1-hour PG group developed diabetes. The respective figures were 16% and 1.8% in the FmH-NONE group. Both FmH-YOD and 1-hour PG predicted diabetes with a negative interaction between FmH-YOD and 1-hour PG (OR 0.72, 95% CI 0.55 to 0.93, p=0.013). Compared with (FmH-NONE/normal 1-hour PG) group, the ORs of incident diabetes in (FmH-NONE/high 1-hour PG), (FmH-YOD/normal 1-hour PG), (FmH-YOD/high 1-hour PG) groups were 7.4 (95% CI 1.6 to 35.1, p=0.011), 18 (95% CI 3.3 to 98.1, p=0.001) and 28.2 (95% CI 5.5 to 145.9, p<0.001), respectively. In ROC analysis, the C-statistics of 1-hour PG dropped from 0.83 (95% CI 0.76 to 0.90, p<0.001) in the FmH-NONE group to 0.69 (95% CI 0.62 to 0.76, p<0.001) in the FmH-YOD group (difference=0.14 (95% CI 0.04-0.24), p=0.006) where fasting PG (FPG) was the best predictor (0.792 (95% CI 0.730-0.853), p<0.001).

Conclusions: FPG outperformed 1-hour PG in predicting incident diabetes in people with FmH-YOD, calling for precise classification and preventive strategies.

Introduction: The effects of different glucose metabolic states and diabetes-controlled status on asymptomatic carotid atherosclerosis has not been well investigated. Herein, we aimed to investigate the association of different diabetes status with asymptomatic carotid plaques and carotid intima-media thickness (CIMT).

Research design and methods: 4752 participants aged over 40 years, free of stroke or myocardial infarction, from the China National Stroke Screen Survey programme were enrolled. Carotid plaque and CIMT were assessed using duplex ultrasonography. Logistic regression analysis was used to assess the relationship between diabetes status and the presence of asymptomatic carotid plaques or abnormal CIMT.

Results: A total of 1977 (41.6%) subjects had carotid plaques and 804 (16.9%) had abnormal CIMT. In multivariate analyses, compared with normoglycemia, individuals with pre-diabetes showed significantly higher odds of asymptomatic carotid plaques (OR 1.22, 95% CI 1.03 to 1.45) and patients with diabetes also had higher odds (OR 1.66, 95% CI 1.41 to 1.92). Diabetes (OR 1.79, 95% CI 1.50 to 2.14) was associated with vulnerable plaques, while pre-diabetes was not (OR 1.17, 95% CI 0.96 to 1.43). Poorly controlled diabetes (HbA1c ≥7.5%) had higher odds of carotid plaques (OR 1.93, 95% CI 1.53 to 2.44), especially of vulnerable plaques (OR 2.03, 95% CI 1.55 to 2.67). No significant association was found between diabetes and abnormal CIMT.

Conclusions: Pre-diabetes and diabetes, especially poorly controlled diabetes, were associated with increased odds of asymptomatic carotid plaques. Implementing the most effective strategies to achieve optimal glycemic control is crucial for the prevention and management of atherosclerosis.

Introduction: Pre-diabetes comprises diverse subphenotypes linked to varying complications, type 2 diabetes, and mortality outcomes. This study aimed to explore these outcomes across different pre-diabetes subphenotypes.

Research design and methods: The dataset included adults without type 2 diabetes with baseline HbA1c and fasting plasma glucose (FPG) measurements from Siriraj Hospital, Bangkok, Thailand. The participants were classified into six subphenotypes via the k-means clustering method on the basis of age, body mass index, FPG, HbA1c, high-density lipoprotein cholesterol and alanine aminotransferase levels. The incidences of type 2 diabetes, long-term vascular complications and mortality were compared among subphenotypes over a median follow-up of 8.8 years, employing Kaplan-Meier curves and Cox regression analysis adjusted for sex, statin use and hypertension status.

Results: Among the 4915 participants (mean age 60.1±10.1 years; 54.6% female), six clusters emerged: cluster 1, low risk (n=650; 13.2%); cluster 2, mild dysglycemia elderly (n=791; 16.1%); cluster 3, severe dysglycemia obese (n=1127; 22.9%); cluster 4, mild dysglycemia obese (n=963; 19.7%); cluster 5, severe dysmetabolic obese (n=337; 6.9%); and cluster 6, severe dysglycemia elderly (n=1042; 21.2%). Clusters were classified into diabetes risk subgroups: low risk (clusters 1 and 4) and high risk (clusters 3 and 5). Cluster 6 exhibited the highest risk, with significantly increased incidences of macrovascular complications (adjusted HR 2.22, 1.51-3.27) and type 2 diabetes (1.73, 1.42-2.12). In contrast, cluster 4 demonstrated the lowest risk, with significantly decreased incidences of new chronic kidney disease (0.65, 0.44-0.96), microvascular complications (0.62, 0.43-0.89) and mortality (0.25, 0.10-0.63).

Conclusions: Our pre-diabetes phenotyping approach effectively provides valuable insights into the risk of type 2 diabetes, vascular complications and mortality in individuals with pre-diabetes. Those with high-risk phenotypes should be prioritized for type 2 diabetes and cardiovascular interventions to mitigate risks.

Introduction: In a cohort of families of school-age children (8-12.99 years old) with type 1 diabetes, we examined the stability of parent and child diabetes-related distress (DRD) over 6 months and the associations between parent and child DRD and child glycated hemoglobin (HbA1c) over time.

Research design and methods: We recruited families from two large pediatric hospital systems in the USA and used validated measures of parent (Parent Problem Areas in Diabetes-Child, PPAID-C) and child (Problem Areas in Diabetes-Child, PAID-C) DRD and children's HbA1c. We collected data at baseline and 6 months. We calculated minimal clinically important differences in PPAID-C and PAID-C to examine DRD stability and used a linear regression model to examine associations between PPAID-C and PAID-C scores and child HbA1c over time.

Results: We recruited n=132 parent-child dyads (mean child age=10.23±1.5 years; 50% male, 86% non-Hispanic white). 60% of children and 55% of parents reported stable DRD levels, 20% of children and 14% of parents reported increasing DRD levels, and 20% of children and 31% of parents reported decreasing DRD levels from baseline to 6 months. In the regression model, child HbA1c and DRD scores at baseline significantly predicted child HbA1c 6 months later, β=0.013, t(157)=2.32, p=0.02.

Conclusions: Across 6 months, DRD remained stable or increased in 80% of school-aged children and 69% of parents. Only child HbA1c and DRD at baseline predicted higher child HbA1c 6 months later. Our results suggest it may be valuable to screen families of school-age children for DRD routinely and to develop treatments to help them reduce DRD.